CA
JAZZ icon

Claris Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Claris Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$334 – 610
2024
Q3 		$334 Buy
+3
New +$329 ﹤0.01% 792

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Claris Advisors's JAZZ Position: Q4 2024 in Review

Claris Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 3 shares — an estimated $334 sold.

Claris Advisors first reported a position in JAZZ in Q3 2024 and held it in 1 quarter. The position peaked at $334 in Q3 2024. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Claris Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 3 Jazz Pharmaceuticals shares in Q4 2024, an estimated $334.
  • Claris Advisors first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Jazz Pharmaceuticals position peaked at $334 in Q3 2024.
  • 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.